Filing · LD-2 quarterly report
Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 20, 2026
Expenses
$100,000
What this organization spent lobbying with its own staff.
Reported using the LDA's own definitions (method A): the three
LDA methods count different costs, so an expenses figure is
not comparable across filers that used different ones.
Client based in
Virginia
Government bodies contacted
4
Lobbying activity
1
SAFE Drugs Act (H.R.6509/ S.3794); Diabetes Act (S. 4037) and competitive bidding program; INSULIN Act (H.R. 10227/ S. 4189); Diabetes foot health (H.R. 7905/H.R. 1616/S. 4070/ S. 1805); Childhood Diabetes Reduction Act (S. 5026); Special Diabetes Program Reauthorization (NIH and IHS); Appropriations for National Institutes of Health and Centers for Disease Control and Prevention; Issues related to insurance reform.